The Oligonucleotide Synthesis Facility was established in response to the need to provide quality synthetic oligonucleotides to the University of Pittsburgh Cancer Institute (UPCI) members and other investigators in the Pittsburgh research community. The Facility arose from a demonstrated need for oligonulceotides in projects ranging from molecular biology to macromolecular crystallography. The Facility offers both crude and purified oligonucleotides at the 0.05, 0.2 and 1 micromole scales. The yield for each synthesis is assayed and the DNA is dissolved in water, ready for use by the investigator. A DNA Synthesis Advisory Committee, including members of the UPCI, was established to oversee the operation of the Facility. This committee meets yearly to review the performance of the Facility, establish user fees and set protocols to keep the Facility running efficiently. Dr. Graham Hatfull, Chairman of the Department of Biological Sciences, University of Pittsburgh, is the director. He is a renowned molecular biologist and a member of the Molecular and Cellular Oncology Program (need to verify this!). The daily operations such as performing the syntheses, data analysis, quality control and maintenance procedures are carried out by manager, Patricia Wells Gruber and the research specialist, David Close. The Facility can generate high purity oligonucteotidcs quickly and at a reasonable cost. Chemical costs have been progressively discomated in response to the increased volume of orders. The quality, cost and rapid turnaround time make this facility a vital part of the research community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-20
Application #
7494657
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
20
Fiscal Year
2007
Total Cost
$76,730
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Lee, Young-Sun; Lee, Dae-Hee; Choudry, Haroon A et al. (2018) Ferroptosis-Induced Endoplasmic Reticulum Stress: Cross-talk between Ferroptosis and Apoptosis. Mol Cancer Res 16:1073-1076
Tong, Jingshan; Zheng, Xingnan; Tan, Xiao et al. (2018) Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. Cancer Res 78:4704-4715
Menk, Ashley V; Scharping, Nicole E; Rivadeneira, Dayana B et al. (2018) 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med 215:1091-1100
Wang, Yue; Wang, Zehua; Xu, Jieni et al. (2018) Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun 9:3192
Saydmohammed, Manush; Vollmer, Laura L; Onuoha, Ezenwa O et al. (2018) A High-Content Screen Reveals New Small-Molecule Enhancers of Ras/Mapk Signaling as Probes for Zebrafish Heart Development. Molecules 23:
Gough, Albert; Shun, Tong Ying; Taylor, D Lansing et al. (2018) Integrating Analysis of Cellular Heterogeneity in High-Content Dose-Response Studies. Methods Mol Biol 1745:25-46
Fletcher, Rochelle; Wang, Yi-Jun; Schoen, Robert E et al. (2018) Colorectal cancer prevention: Immune modulation taking the stage. Biochim Biophys Acta Rev Cancer 1869:138-148
Caves, Elizabeth A; Cook, Sarah A; Lee, Nara et al. (2018) Air-Liquid Interface Method To Study Epstein-Barr Virus Pathogenesis in Nasopharyngeal Epithelial Cells. mSphere 3:
Singh, Renu; Mehrotra, Shailly; Gopalakrishnan, Mathangi et al. (2018) Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemother Pharmacol :
Li, Changfeng; Zhang, Ying; Cheng, Xing et al. (2018) PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Dev Cell 46:441-455.e8

Showing the most recent 10 out of 1187 publications